Authors
Michael Kavanaugh
Published in
Magnetic resonance imaging clinics of North America. Volume 35. Issue 1. Pages 189-197. Epub Oct 23, 2026.
Abstract
Neuroendocrine neoplasms are a rare and heterogeneous group of neoplasms originating from a wide range of primary organs, with differing treatment approaches and prognoses. Most well-differentiated neuroendocrine tumors (NETs), particularly gastroenteropancreatic NETs, highly express somatostatin receptors (SSTRs) on their cell membranes, and thus SSTR-targeting therapies play a crucial role in management. SSTR-targeting peptide receptor radionuclide therapy uses radiolabeled somatostatin analogs that decay via particle emission, resulting in targeted delivery of therapeutic radiation to tumor sites while minimizing nontarget toxicity.
PMID:
43039499
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0